Literature DB >> 21205752

Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.

Hiroto Inaba1, Margherita Londero, Scott H Maurer, Mihaela Onciu, Yubin Ge, Jeffrey W Taub, Jeffrey E Rubnitz, Susana C Raimondi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21205752      PMCID： PMC3527733          DOI： 10.1200/JCO.2010.32.3634

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

Review 1.  Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia?

Authors:  Alan S Gamis; Joanne M Hilden
Journal:  J Pediatr Hematol Oncol       Date:  2002-01       Impact factor: 1.289

2.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

3.  An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis.

Authors:  Luciana M Hollanda; Carmen S P Lima; Anderson F Cunha; Dulcinéia M Albuquerque; José Vassallo; Margareth C Ozelo; Paulo P Joazeiro; Sara T O Saad; Fernando F Costa
Journal:  Nat Genet       Date:  2006-06-18       Impact factor: 38.330

4.  Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.

Authors:  J W Taub; X Huang; L H Matherly; M L Stout; S A Buck; G V Massey; D L Becton; M N Chang; H J Weinstein; Y Ravindranath
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

5.  GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

Authors:  Yubin Ge; Mark L Stout; Dana A Tatman; Tanya L Jensen; Steven Buck; Ronald L Thomas; Yaddanapudi Ravindranath; Larry H Matherly; Jeffrey W Taub
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

6.  Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.

Authors:  B J Lange; N Kobrinsky; D R Barnard; D C Arthur; J D Buckley; W B Howells; S Gold; J Sanders; S Neudorf; F O Smith; W G Woods
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

Review 7.  Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.

Authors:  Anindita Roy; Irene Roberts; Alice Norton; Paresh Vyas
Journal:  Br J Haematol       Date:  2009-07-06       Impact factor: 6.998

8.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.

Authors:  Joshua Wechsler; Marianne Greene; Michael A McDevitt; John Anastasi; Judith E Karp; Michelle M Le Beau; John D Crispino
Journal:  Nat Genet       Date:  2002-08-12       Impact factor: 38.330

9.  Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes.

Authors:  Nataly Apollonsky; Ashok Shende; Ihsane Ouansafi; Judith Brody; Mark Atlas; Banu Aygun
Journal:  J Pediatr Hematol Oncol       Date:  2008-11       Impact factor: 1.289

Review 10.  Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Ana C Xavier; Yubin Ge; Jeffrey W Taub
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568
  10 in total
  4 in total

Review 1.  Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.

Authors:  Rintaro Ono; Daisuke Hasegawa; Shinsuke Hirabayashi; Takahiro Kamiya; Kenichi Yoshida; Satoko Yonekawa; Chitose Ogawa; Ryota Hosoya; Tsutomu Toki; Kiminori Terui; Etsuro Ito; Atsushi Manabe
Journal:  Eur J Pediatr       Date:  2014-09-30       Impact factor: 3.183

Review 2.  Transient leukemia in a newborn without Down syndrome: case report and review of the literature.

Authors:  Laurence Rozen; Sophie Huybrechts; Laurence Dedeken; Catherine Heijmans; Barbara Dessars; Pierre Heimann; Frédéric Lambert; Denis F Noubouossie; Alina Ferster; Anne Demulder
Journal:  Eur J Pediatr       Date:  2013-11-20       Impact factor: 3.183

3.  Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.

Authors:  Hiroto Inaba; Yinmei Zhou; Oussama Abla; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Eveline de Bont; Tai-Tsung Chang; Ursula Creutzig; Michael Dworzak; Sarah Elitzur; Alcira Fynn; Erik Forestier; Henrik Hasle; Der-Cherng Liang; Vincent Lee; Franco Locatelli; Riccardo Masetti; Barbara De Moerloose; Dirk Reinhardt; Laura Rodriguez; Nadine Van Roy; Shuhong Shen; Takashi Taga; Daisuke Tomizawa; Allen E J Yeoh; Martin Zimmermann; Susana C Raimondi
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

4.  A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.

Authors:  Ana C Xavier; Holly Edwards; Alan A Dombkowski; Tugce B Balci; Jason N Berman; Graham Dellaire; Chengzhi Xie; Steven A Buck; Larry H Matherly; Yubin Ge; Jeffrey W Taub
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.